drugset / Trial / NCT05486377

Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia

NCT05486377

Phase 4 Completed 96 enrolled Seoul National University Bundang Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

In anesthesia for ablation for cardiac arrhythmias, abrupt hemodynamic changes or fatal arrhythmias can be seen frequently. Remimazolam is a novel ultra-short acting benzodiazepine that provides good hemodynamic stability compared to conventional anesthetic agents. This study aims to investigate whether remimazolam reduces vasoactive agent use during cryo/radiofrequancy ablation under general anesthesia, compared to desflurane(RCT).

Timeline

Start
2022-08-02
Primary completion
2023-05-19
Completion
2023-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Remimazolam Small molecule Intravenous